Coreline Soft and Optellum Seek to Enhance AI Applications in Lung Cancer Management

Collaboration for Enhanced Lung Cancer Care

In a significant development in the field of healthcare technology, Coreline Soft and Optellum have jointly announced their intent to collaborate on advancing artificial intelligence (AI) applications specifically designed for lung cancer management. This partnership aims to improve the entire pathway for lung nodule detection and management, thereby enhancing patient outcomes in a disease area that continues to pose urgent healthcare challenges worldwide.

The collaboration is focused on integrating Coreline Soft's FDA-cleared AVIEW Lung Nodule CAD software with Optellum's LungOS® platform. This innovative move is aimed at providing clinicians with an end-to-end AI-powered system that facilitates the entire thoracic care workflow. The goal is to establish a seamless connection between Coreline's advanced imaging detection capabilities and Optellum's risk assessment and care management functionalities. By doing so, both companies aim to ensure that the journey from initial detection of lung nodules to follow-up care is more cohesive and efficient.

Lung cancer is recognized as one of the most pressing health issues globally. Current statistics indicate that early diagnosis dramatically increases a patient's chances of survival, with a five-year relative survival rate nearing 64% for localized lung cancer compared to only 9% for advanced stages. Annually, around 20 million chest CT scans are conducted in the United States, leading to incidental detections of lung nodules in over 1.6 million patients. Moreover, a substantial 10% of these nodules that measure over 8 mm are likely malignant. To address these alarming figures, the Optellum-Coreline Soft collaboration is designed to aid clinicians and healthcare systems in prioritizing and managing the care of patients with lung nodules more effectively, enabling earlier intervention and assessment.

Advancing Lung Cancer Care

Dr. Johnathan Watkins, CEO of Optellum, expressed the importance of this collaboration, stating, "Optellum is building LungOS® into a unified operating system for lung cancer and thoracic care. Our collaboration reflects a shared commitment to providing clinicians with superior tools needed for efficient lung nodule assessments." The integration of Coreline Soft’s sophisticated detection software is expected to complement Optellum's expertise in nodule risk assessment and management, creating an enriched environment for patient care.

Jin Kook Kim, CEO of Coreline Soft, added, "We are excited about the potential of collaborating with Optellum. By linking Coreline’s experience in detecting lung nodules with Optellum’s structured management approach, we expect to play a crucial role in shaping a more effective lung cancer care model." Coreline Soft's AVIEW platform is already well-regarded for supporting lung cancer screening and has been successfully utilized in over 3 million clinical cases across various international settings, establishing a strong foundation for their future endeavors.

The Impact of AI in Medical Imaging

The partnership is particularly timely, considering the dramatic reliance on advanced imaging technologies in modern healthcare. AI tools are emerging as transformative assets in the early diagnosis and treatment of diseases, particularly lung cancer, which is notoriously difficult to detect in early stages. With the incorporation of AI, healthcare providers can enhance the accuracy of diagnostics, significantly reducing the amount of time it takes to develop effective treatment plans for patients.

Optellum’s LungOS® platform integrates a system that encompasses patient discovery through AI, along with community support for lung nodule identification, risk stratification, and patient management. This comprehensive platform represents a leap forward in patient care, offering enhanced efficiency for healthcare professionals.

Conclusion

In conclusion, the collaborative efforts of Coreline Soft and Optellum signify a proactive approach to tackling one of today’s most formidable health challenges. Both firms are committed to leading innovations that leverage AI technology, ultimately aiming for a future state where patients with lung nodules receive timely, efficient care without delay. This partnership not only symbolizes a high-profile combination of technological capabilities but also underscores the potential of AI to reshape the landscape of healthcare and improve outcomes for lung cancer patients.

Through this partnership, both Coreline Soft and Optellum aspire to catalyze a paradigm shift in how lung cancer is diagnosed and treated, making progressive strides towards a more efficient and effective healthcare model.